Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Sarcoma 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 30Breast Neoplasms 29Glioblastoma 23Multiple Myeloma 21Glioma 20Lymphoma 19Pancreatic Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 16Brain Neoplasms 14Sarcoma 13Squamous Cell Carcinoma of Head and Neck 12Rectal Neoplasms 11Neoplasm Metastasis 11Melanoma 11Lymphoma, Non-Hodgkin 11Thyroid Neoplasms 10Ovarian Neoplasms 10Oropharyngeal Neoplasms 10Neuroblastoma 9Mouth Neoplasms 9Medulloblastoma 9Lymphoma, Follicular 9Ependymoma 9Colorectal Neoplasms 9Central Nervous System Neoplasms 9Astrocytoma 9

Interventions

pembrolizumab 6Cisplatin 5Radiotherapy 4Paclitaxel 3Nivolumab 3lenvatinib 2Specimen Handling 2Platinum 2Papillomavirus Vaccines 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Gemcitabine 2Carboplatin 2CTLA-4 Antigen 2Bleomycin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2zimberelimab 1rocakinogene sifuplasmid 1liposomal doxorubicin 1durvalumab 1dostarlimab 1cemiplimab 1belzutifan 1antineoplaston AS 2-1 1antineoplaston A10 1alovudine 1aldesleukin 1Watchful Waiting 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Vulvar Neoplasms × Magnetic Resonance Spectroscopy × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03403465 2026-02-27

Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers

Duke University

Phase 2 Active not recruiting
90 enrolled
GastrointestinalGynecologic

Anal Canal Carcinoma, Uterine Cervical Neoplasms, Esophageal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡